动物造模 z-bio 2021-02-20 307

　　Researchers at the Johns Hopkins University School of Medicine said in their studies on mouse and human cells that they have developed a small but effective way to prevent preterm birth. The drug delivered from the vagina contains nanometer (one billionth of a meter) drug particles, which easily penetrate the vaginal wall to reach the uterine muscles and prevent uterine contractions. If proven effective in humans, this treatment may be one of the only clinical options to prevent preterm birth. The FDA recommends that the only drug Makena (17-hydroxyprogesterone caproate) approved for this purpose be removed from the market. It is estimated that 15 million preterm births occur every year, which is the main cause of sudden infant death in the world. There are few indicators to predict which pregnant women will cause preterm birth, but in all cases, about one-third are related to inflammation of the reproductive tract. This situation not only puts the baby at birth with a low weight and a risk of lung dysplasia, but it is also related to the damage of the brain to the developing fetus.

　　 According to reports, the latest experimental therapy uses a technology developed by scientists at the Johns Hopkins University Nanomedicine Center. Its active ingredients are progesterone (a hormone that regulates female reproduction) and tricolostatin A (TSA), a histone deacetylase (HDAC) inhibitor that regulates gene expression. To prepare for treatment, the drug is first crushed into bacteria with a diameter of about 200-300 nanometers or less, forming microcrystals. A layer of stabilizing compound is then applied to the nanocrystal to prevent it from sinking into the protective mucus layer of the human body, thereby absorbing and removing foreign matter. Dr. Laura Ensign, associate professor of ophthalmology at the Johns Hopkins University School of Medicine and associate professor of obstetrics and gynecology, said: "This means that fewer drugs can be used to effectively reach other parts of the female reproductive tract." , Research co-author, expert in nanomedicine and drug delivery systems. To test their treatment, the researchers used mice that mimic inflammation-related diseases that can cause premature birth in humans. They found that the experimental treatment prevented the mice from entering preterm labor. Neurological examination of puppies born to mothers who received this treatment did not reveal any abnormalities. The researchers also applied this drug combination to human uterine cells grown in the laboratory. They reported that the combination of drugs reduced the shrinkage of the test sample.